TransMedics Group, Inc. (TMDX) Average EV/Sales Ratio
The current ev/sales ratio for TransMedics Group, Inc. (TMDX) is 5.12x as of Saturday, June 20, 2026, shown against its trailing averages.
Average EV/Sales Ratio Chart
TMDX EV/Sales Ratio Averages
EV/SALES RATIO CURRENT
5.12x
EV/SALES RATIO TTM
8.59x
EV/SALES RATIO 3Y
11.18x
EV/SALES RATIO 5Y
16.32x
EV/SALES RATIO 10Y
18.00x
EV/SALES RATIO 15Y
18.00x
EV/SALES RATIO 20Y
18.00x
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein